Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis

J Neurol Sci. 2020 Dec 15:419:117175. doi: 10.1016/j.jns.2020.117175. Epub 2020 Oct 11.

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons that results in progressive paralysis and muscular atrophy. There are many molecules and genes involved in neuromuscular degeneration in ALS; among these, matrix metalloproteinases (MMPs). MMPs play an important role in the pathology of ALS, and MMP-1, 2, 3, and 9 might serve as disease progression markers. Tissue inhibitors of metalloproteinases (TIMPS) might also function as progression markers in ALS because they participate in regulating the proteolytic activity of MMPs. Moreover, a diversity of genes also plays a role in the pathogenesis of ALS; most MMPs-coding genes present variants related to the pathological proteolytic activity. This short review, however, will focus on the role of matrix metalloproteinases in ALS.

Keywords: Amyotrophic lateral sclerosis; Matrix metalloproteinase; Neurodegenerative disease.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis* / genetics
  • Humans
  • Matrix Metalloproteinases / genetics
  • Motor Neurons
  • Neurodegenerative Diseases*

Substances

  • Matrix Metalloproteinases